Main Uses and Benefits of Delatestryl (Testosterone)

Delatestryl is an injectable form of testosterone enanthate, an androgenic hormone. It is primarily used to replace or supplement the natural testosterone produced by the body when levels are insufficient.

Primary Indications

Primary Hypogonadism

Delatestryl is indicated for men with primary hypogonadism, a condition where the testes do not produce adequate amounts of testosterone. This can be caused by various factors, including:

• Testicular failure due to cryptorchidism (undescended testes).
• Bilateral torsion (twisting of the testes).
• Orchitis (inflammation of the testes).
• Orchiectomy (surgical removal of the testes).
• Klinefelter syndrome.
• Toxic damage from chemotherapy or heavy metals.

Hypogonadotropic Hypogonadism

It is also used to treat hypogonadotropic hypogonadism, also known as secondary hypogonadism. In this condition, the testes are functional, but the signals from the pituitary gland or hypothalamus that trigger testosterone production are missing or insufficient. This may be due to genetic deficiencies, tumors, or trauma.

Delayed Puberty

In certain cases, Delatestryl may be used to stimulate puberty in males who experience a significant delay in the onset of sexual maturation. This application is typically reserved for instances where the delay is not a result of a primary pathological condition but is causing significant emotional or psychological distress.

Metastatic Breast Cancer

In a secondary role, Delatestryl may be used as a palliative treatment for individuals with inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal. The goal in these cases is to antagonize the effects of estrogen and slow tumor progression.

Expected Benefits

When used for hormone replacement therapy, the primary benefit of Delatestryl is the restoration of testosterone levels to a physiological range. This normalization can lead to several improvements in physical and metabolic health:

• Development of Secondary Sexual Characteristics: Supports the maintenance of male physical traits, such as body hair distribution and deepening of the voice.
• Bone Density Maintenance: Androgens play a critical role in maintaining bone mineral density and reducing the risk of osteoporosis.
• Muscle Mass and Strength: Testosterone contributes to the maintenance of lean muscle mass and physical strength.
• Libido and Sexual Function: Replacement therapy often helps in restoring sexual desire and improving erectile function in cases where deficiency was the underlying cause.
• Mood and Energy Levels: Many individuals report improvements in overall energy, a reduction in fatigue, and a more stable mood once hormone levels are balanced.

Official Eligibility Rules for Delatestryl

Delatestryl (Testosterone Enanthate) is officially indicated for adult males with a confirmed deficiency or absence of endogenous testosterone, known as hypogonadism (primary or hypogonadotropic). It may also be used in selected males with delayed puberty and, in restricted oncological settings, for postmenopausal women with advancing metastatic mammary cancer.

---

Populations For Whom Use is Contraindicated:

• Men with known or suspected carcinoma of the prostate or breast.
• Women who are or may become pregnant, and nursing/breastfeeding women, due to the risk of fetal harm.
• Any patient with a known hypersensitivity to the active ingredient or excipients.

---

Populations Requiring Conditional Use:

Regulatory documents stipulate caution for patients with cardiac, renal, or hepatic disease due to the risk of edema (fluid retention) and congestive heart failure. Use in patients with pre-existing sleep apnea, epilepsy, or migraine also requires caution, as the conditions may be aggravated.

Age and Purpose Restrictions:

General use in children under 18 years of age is not indicated as safety and efficacy have not been established. The FDA states that safety and efficacy for treating "age-related hypogonadism" have not been established. The medicine must not be used for athletic performance enhancement.

Interactions with other medicines and products

The interaction profile of Delatestryl (Testosterone Enanthate) is defined by documented effects on the metabolism of testosterone and altered activity of co-administered medicines, as stated in regulatory labeling. The following clinically significant interactions require attention during co-administration:

---

Pharmacodynamic and Metabolic Effects

The co-administration of testosterone with oral anticoagulants, particularly coumarin derivatives, may lead to a potentiated anticoagulant effect. This pharmacodynamic interaction necessitates close and frequent monitoring of clotting status (Prothrombin Time/INR). Separately, the metabolic effects of androgens may decrease blood glucose levels, requiring potential dosage reduction for insulin or other antidiabetic agents.

---

Pharmacokinetic and Fluid Balance Interactions

Co-administration with microsomal enzyme inducers, such as barbiturates, may increase the metabolic clearance of testosterone, which can lead to reduced hormone exposure. Conversely, testosterone use has been associated with increased serum levels of Oxyphenbutazone. A separate pharmacodynamic interaction involves combining testosterone with corticosteroids or ACTH, which carries an enhanced tendency toward edema (fluid retention). This risk is explicitly noted as a specific caution for patients with pre-existing cardiac, renal, or hepatic disease. No mandatory timing-based separation rules or food/alcohol/supplement interactions are documented for the injectable solution.

Mechanism of Action: Delatestryl (Testosterone)

Delatestryl, which supplies exogenous testosterone, functions by modulating both genomic and metabolic pathways within target cells. The hormone readily crosses the cell membrane and acts as an agonist by binding to the intracellular Androgen Receptor (AR), a type of nuclear receptor. This activated complex then translocates to the nucleus to initiate gene transcription by binding to specific DNA sequences. This alters the production of numerous proteins, which is the foundational mechanistic step governing anabolic (protein synthesis) and androgenic effects.

Simultaneously, testosterone is processed by two key enzymes: 5alpha-reductase converts it into dihydrotestosterone (DHT), a metabolite with a higher affinity for the AR, while aromatase converts it to estradiol ( E2), which modulates Estrogen Receptor ( ER) signaling. Systemically, elevated circulating levels of the hormone engage in negative feedback on the Hypothalamic-Pituitary-Gonadal (HPG) axis). This suppresses the release of Gonadotropin-Releasing Hormone (GnRH) and pituitary hormones ( LH and FSH), thereby modulating the endogenous neuroendocrine signaling system.

Official Administration Guidelines for Delatestryl

Delatestryl (Testosterone Enanthate Injection) is administered via deep intramuscular injection for its indicated uses. Dosage and duration of therapy are highly individualized and depend on the patient's age, diagnosis, clinical response, and the appearance of adverse effects.

Administration Scope	Guideline
Route	Deep Intramuscular (IM) injection, typically into the gluteal muscle.
Frequency	Typically administered once every two to four weeks. Injections more frequently than every two weeks are rarely indicated.
Dosing for Hypogonadism (Males)	Suggested dosage is 50 mg to 400 mg every 2 to 4 weeks. Total doses above 400 mg per month are generally not required.
Preparation	The solution should be visually inspected for particulate matter or discoloration before use; it is a clear, colorless to pale yellow solution. The preparation must be injected slowly.

Procedural Requirements

Before initiating therapy for hypogonadism, the diagnosis must be confirmed by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and are below the normal range.

The injection procedure requires following the usual precautions for intramuscular administration, including the explicit avoidance of intravascular injection. For male patients with delayed puberty, the chronological and skeletal ages must be considered when determining the initial dose and subsequent adjustments. The effect on bone maturation should be monitored by assessing bone age (via X-ray of the wrist and hand) every six months.

Delatestryl is designed for prolonged action after administration, which is why the dosing interval is generally between two and four weeks. Adherence to the prescribed schedule and dose, which is individualized to avoid excessively high or low hormone levels, is a key component of the overall treatment plan.

Research Evidence / Overview of Studies

Efficacy in Osteoarthritis

Research has explored whether the compound may improve joint mobility and may lessen stiffness in individuals with mild-to-moderate osteoarthritis. Evaluations suggest that an observed effect may assist in managing daily symptoms. The typical duration of these studies ranged from 8 to 12 weeks.

Multiple studies report findings compared to placebo. Studies reported that data points evaluated include the WOMAC pain and function scores. It is not yet clear whether the effects persist after discontinuation of the compound.

Areas of Research Focus

Studies have investigated the underlying biological processes relevant to the compound's activity. Research has also examined the potential ways this activity may interact with cartilage degradation. These investigations are intended to further characterize the compound's studied effects.

Research in Bone Health

Research evaluated whether the compound, when combined with key nutrients, is associated with changes in bone health markers. In a cohort of elderly individuals, research evaluated whether the combination of Compound X and Vitamin D was associated with changes in bone density. Further research is needed to determine its role in preventing fractures.

Long-term use has been studied and research explored whether the compound is associated with ongoing management of pain. One study suggests that combining the compound with physical therapy may be associated with different outcomes.

Adverse Event Profile

Studies reviewed the overall adverse event profile across all trials. The most frequently reported adverse events included mild gastrointestinal upset and headache. The studies assessed the incidence and severity of these events against placebo.

Serious adverse events had a low reported incidence across all trials. Research indicates that it is not yet clear whether the compound increases the risk of long-term cardiovascular events, and this remains an area of active investigation.

Key Studies & References

1. Prevalence of Osteoporosis and the Role of Testosterone and Vitamin D Deficiency in Elderly Men: A Cross-Sectional Study
2. DELATESTRYL (Testosterone Enanthate) Prescribing Information (Warning and Precautions)

Common questions about Delatestryl (Testosterone) (FAQ)

Q: What is the main difference between Delatestryl and other types of testosterone injections like cypionate?

Official product information describes Delatestryl as a testosterone enanthate injection, which is a long-acting ester. This structure allows the product to be dissolved in an oil vehicle, such as sesame oil, for deep intramuscular injection. This controlled-release mechanism is intended to provide stable therapeutic hormone levels over a prolonged period, typically 2 to 4 weeks.

Q: Why is Delatestryl sometimes prescribed for women?

Official eligibility rules state that Delatestryl is indicated for use in postmenopausal women in restricted oncological settings. Specifically, the medication may be used to address advancing metastatic mammary cancer.

Q: Does Delatestryl contain sesame oil, and is this an allergy concern?

Regulatory information indicates that testosterone enanthate is commonly formulated in sesame oil. As this is a component of the medication, the product is formally contraindicated for any patient with a known history of hypersensitivity to sesame oil or other inactive ingredients.

Q: Can taking Delatestryl affect my blood pressure?

According to the official product label, testosterone can be associated with an increase in blood pressure. Elevated blood pressure can contribute to cardiovascular risk over time. Blood pressure is often monitored periodically while using the product, as noted in official guidelines.

Q: Does Delatestryl treatment have an effect on cholesterol levels?

Official safety data indicates that androgens may adversely affect serum lipids. This includes the potential for the product to lower HDL (known as 'good cholesterol') and elevate LDL (known as 'bad cholesterol') levels.

Q: What are the major symptoms of a serious allergic reaction to Delatestryl?

Serious allergic reactions, known as anaphylaxis, have been reported in postmarketing data. Signs may include a sudden onset of symptoms such as rash, hives, itching, or swelling of the lips, tongue, or face. Difficulty breathing is also a serious symptom that requires immediate attention.

Q: Are there any specific concerns about using Delatestryl in older men (geriatric population)?

Regulatory documents note that geriatric patients may face an increased risk for the development of prostatic hypertrophy (enlargement) and prostatic carcinoma. Furthermore, the safety and efficacy of the product specifically for treating age-related hypogonadism have not been established.

Q: Is there a risk of Delatestryl affecting liver function?

Prolonged use of high doses of testosterone has been officially associated with rare, serious conditions like peliosis hepatis (blood-filled cysts in the liver) and hepatic neoplasms (liver tumors). If liver function tests become abnormal during treatment, discontinuation of the product may be required.

Q: Can Delatestryl cause changes in mood or behavior, such as increased anger or irritability?

Psychiatric adverse reactions have been reported in postmarketing surveillance. These include changes in behavior such as anger and irritability, as well as other psychological states like anxiety, depression, and suicidal ideation.

Q: Does Delatestryl have any effect on male fertility or sperm count?

Official product information indicates that at large doses, the release of Follicle Stimulating Hormone (FSH) may be suppressed through a negative feedback loop. This mechanism may lead to a suppression of spermatogenesis (sperm production), meaning the drug has the potential to affect sperm count.

Q: Is Delatestryl the same thing as an anabolic steroid?

Official classification indicates that Delatestryl contains testosterone, a naturally occurring male hormone and a Schedule III controlled substance. The drug has been subject to abuse, typically involving high doses, which is often seen in combination with other anabolic steroids.

Q: What is the risk of having a prolonged erection (priapism) while using Delatestryl?

The product label advises that adult or adolescent males should be instructed to report too frequent or persistent erections of the penis. This symptom is noted in product information for its clinical relevance and should be reported to the prescribing healthcare provider.

Q: Is Delatestryl treatment linked to changes in sleep, like worsening sleep apnea?

Official safety information states that testosterone products may worsen sleep apnea, which is a condition where breathing stops or starts repeatedly during sleep. Caution is therefore stipulated for patients who have pre-existing sleep apnea.

Q: Are there certain medical conditions that might be worsened by taking Delatestryl?

Caution is advised for patients with certain pre-existing conditions. These include cardiac, renal, or hepatic (liver) disease due to the increased risk of severe edema (fluid retention), and patients with sleep apnea, as the condition may be aggravated.

Q: What happens to the body’s natural testosterone production when using Delatestryl?

The mechanism of action involves the release of the external hormone engaging in negative feedback on the brain's pituitary gland. This process effectively inhibits the body's natural production of testosterone.

Q: Does Delatestryl interact with any common over-the-counter medications?

Regulatory documentation notes interactions with prescription medications like oral anticoagulants, insulin or other antidiabetic agents, and corticosteroids. The official label specifies interactions with certain medications, including those that may increase blood pressure. A comprehensive list covering every over-the-counter medication is not provided.

Q: Can female patients who use Delatestryl experience physical changes like voice deepening or hair growth?

Official information advises female patients to report symptoms of virilization (masculinizing effects). These physical changes can include hoarseness or deepening of the voice, acne, changes in menstrual periods, or the growth of more facial hair.

Q: What are the possible visual side effects or vision changes associated with Delatestryl?

Postmarketing safety reports have included visual side effects. These reactions can include experiencing blurred vision or other changes in eyesight.

Q: Is there information on the long-term safety of Delatestryl use?

The FDA required labeling changes to reflect a possible increased risk of heart attacks and strokes associated with the use of testosterone, particularly in aging men. The long-term safety of the product remains an area of continued investigation.

Q: How does Delatestryl treatment relate to bone health or bone mineral density?

Testosterone is recognized as an important factor in bone health; official information notes that androgens can accelerate bone maturation in adolescents. Research is also examining the effect of testosterone replacement on bone mineral density in hypogonadal males.

Q: Is it possible to develop a dependence or misuse issue with Delatestryl?

The product is legally classified as a Schedule III controlled substance and has been subject to abuse. Official documentation notes that information regarding the serious cardiovascular and psychiatric adverse reactions associated with misuse should be provided.

Q: What are the expected changes in libido or sexual interest with Delatestryl?

Regulatory data indicates that changes in sexual interest are possible. Both libido increased and libido decreased have been reported as postmarketing adverse events.

Q: What are the signs of high calcium levels in the blood related to Delatestryl use?

In certain patients, such as those with breast cancer or who are immobilized, androgen therapy may lead to dangerously high calcium levels, a condition called hypercalcemia. Signs to watch for may include confusion, increased thirst, or increased urination.

Q: Is it normal to feel a cough or urge to cough right after a Delatestryl injection?

Official safety reports have indicated that patients may experience a cough or urge to cough during or immediately after the injection. This side effect is often described as transient and generally self-limited.

Q: Does Delatestryl affect how the thyroid gland works or how thyroid tests are read?

Testosterone may cause a transient decrease in T4 binding globulin, a protein that carries thyroid hormone in the blood. This change can alter how thyroid function tests are read, and such monitoring is noted as relevant for patients already on thyroid replacement therapy.

Q: How is the use of Delatestryl different for men with low testosterone versus those with delayed puberty?

A key difference in regulatory guidelines involves monitoring. For males with delayed puberty, the effect on bone growth must be tracked by assessing bone age via X-ray every six months. Treatment for delayed puberty is also often brief and requires conservative dosing, compared to long-term replacement therapy.

Q: What are the signs of liver issues that a patient should watch out for while taking Delatestryl?

Due to the risk of liver problems, patients should be aware of certain signs. These may include pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, vomiting, or yellow eyes or skin.

Q: Can Delatestryl cause noticeable weight changes in patients?

According to patient safety information, noticeable weight changes are among the reported side effects. These can include both weight gain and unusual weight gain or loss.

Q: Can Delatestryl affect gum or mouth health if used in a buccal/sublingual form?

Delatestryl is formally an injectable solution administered into the muscle. Issues like gum or mouth irritation are side effects that have been reported with topical (buccal film) testosterone formulations, but not the intramuscular injection.

Q: Can Delatestryl cause changes to my skin, like acne or oiliness?

Acne is officially listed as one of the Most Common side effects, potentially affecting up to 1 in 10 patients. Increased oiliness of the skin has also been reported, as these are known androgenic effects.

Storage and Disposal Requirements

Delatestryl (testosterone enanthate injection) must be stored according to specific regulatory guidelines to maintain its stability and ensure safety.

Storage Conditions

Requirement	Official Condition
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep the injection protected from light and moisture, and do not freeze or expose to excess heat.
Container	Keep the medicine in its original container, tightly closed. Visually inspect the solution for particulate matter before use.

Safety and Disposal

As a Schedule III controlled substance, Delatestryl must be stored securely and out of the reach of children and pets.

Disposal must follow pharmaceutical waste rules: Do not dispose of the medication in the sink, toilet, or household garbage. Patients are instructed to consult a pharmacist or healthcare provider for proper disposal of unused or expired product.